申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0234946A2
公开(公告)日:1987-09-02
The present invention is concerned with compounds of formula (I), physiologically acceptable salts thereof, formulations containing them, their preparation and their use in medicine.
In formula (I)
wherein:
Q and Q1 - Q3 are hydrogen;
A is a group of formula -CONH(CH2)n- , where n is 4 and Q9 is hydrogen;
B is an isopropyl group;
E is a carboxyl group;
Z is a carboxyl or C2.6 carboalkoxy group;
D is a methyl group;
(X) is a naphthyl or indolyl ring system; and
-N Y is a pyrrolidinyl ring; and physiologically acceptable salts thereof; with the condition that when (X) is a naphthyl ring system, the compound of formula (I) is:
N-(1(S)-carboxy-5- [5-(2(R,S)-hydroxy -3-isopropyl- aminopropoxy) naphth-2- ylcarboxamidol pentyl)-(R,S)-alanyl-(S)- proline, or
N-(1(S)- carboxy-5- [8-(2(R,S)- hydroxy-3-isopropyl- aminopropoxy) naphth -2-ylcarboxamido] pentyl)-(R,S)-alanyl-(S)- proline, or a half ester (wherein Z is C2-5 carboalkoxy) of either thereof, and when (X) is an indolyl ring system the compound of formula (I) is
N-(1(S)-carboxy-5- [4-(2(S)- hydroxy-3-isopropyl- aminopropoxy) -1H-indol -2-yl-carboxamido] pentyl)-(S)-alanyl-(S)- proline, or a half ester (wherein Z is C2-5 carboalkoxy) thereof.
本发明涉及式(I)化合物、其生理上可接受的盐、含有它们的制剂、它们的制备及其在医学中的应用。
在式 (I) 中
其中
Q 和 Q1 - Q3 是氢;
A 是式 -CONH(CH2)n- 的基团,其中 n 是 4,Q9 是氢;
B 是异丙基
E 是羧基
Z 是羧基或 C2.6 羧烷氧基
D 是甲基;
(X) 是萘基或吲哚基环系;以及
-N Y 是吡咯烷基环;及其生理学上可接受的盐;条件是当(X)是萘基环系时,式(I)化合物是:
N-(1(S)-羧基-5-[5-(2(R,S)-羟基-3-异丙基-氨基丙氧基)萘-2-甲脒戊基)-(R,S)-丙氨酰-(S)-脯氨酸,或
N-(1(S)-羧基-5-[8-(2(R,S)-羟基-3-异丙基-氨基丙氧基)萘烷-2-基甲酰氨基]戊基)-(R,S)-丙氨酰-(S)-脯氨酸,或其任一者的半酯(其中 Z 为 C2-5 羧基氧基),当(X)为吲哚基环系时,式(I)化合物为
N-(1(S)-羧基-5-[4-(2(S)-羟基-3-异丙基-氨基丙氧基)-1H-吲哚-2-基-甲酰氨基]戊基)-(S)-丙氨酰-(S)-脯氨酸,或其半酯(其中 Z 为 C2-5 羧基烷氧基)。